Long-term compassionate use of cefiderocol to treat chronic osteomyelitis caused by extensively drug-resistant Pseudomonas aeruginosa and extended-spectrum-β-lactamase-producing Klebsiella pneumoniae in a pediatric patient

Zain I. Alamarat, Jessica Babic, Truc T. Tran, Susan H. Wootton, An Q. Dinh, William R. Miller, Blake Hanson, Audrey Wanger, Joshua L. Gary, Cesar A. Arias, Norma Pérez

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

We report a 15 year-old Nigerian adolescent male with chronic osteomyelitis caused by an extensively drug-resistant (XDR) Pseudomonas aeruginosa strain of sequence type 773 (ST773) carrying blaNDM-1 and an extended spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae strain. The patient developed neurological side effects in the form of circumoral paresthesia with polymyxin B and asymptomatic elevation of transaminases with aztreonam (used in combination with ceftazidime-avibactam). Cefiderocol treatment for 14 weeks plus bone implantation resulted in apparent cure and avoided amputation.

Original languageEnglish (US)
Article numbere01872-19
JournalAntimicrobial Agents and Chemotherapy
Volume64
Issue number4
DOIs
StatePublished - 2020

Keywords

  • Cefiderocol
  • Chronic osteomyelitis
  • ESBL-producing klebsiella pneumoniae
  • Pediatric
  • XDR pseudomonas aeruginosa

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Long-term compassionate use of cefiderocol to treat chronic osteomyelitis caused by extensively drug-resistant Pseudomonas aeruginosa and extended-spectrum-β-lactamase-producing Klebsiella pneumoniae in a pediatric patient'. Together they form a unique fingerprint.

Cite this